KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Abbott Laboratories (NYSE:ABT – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Profitability
This table compares KORU Medical Systems and Abbott Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
| Abbott Laboratories | 9.75% | 17.97% | 9.22% |
Valuation & Earnings
This table compares KORU Medical Systems and Abbott Laboratories”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $41.13 million | 3.46 | -$2.64 million | ($0.04) | -77.50 |
| Abbott Laboratories | $44.33 billion | 4.27 | $6.52 billion | $2.68 | 40.83 |
Abbott Laboratories has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
58.6% of KORU Medical Systems shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 18.5% of KORU Medical Systems shares are owned by insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
KORU Medical Systems has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for KORU Medical Systems and Abbott Laboratories, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 1 | 4 | 0 | 2.50 |
| Abbott Laboratories | 0 | 5 | 21 | 2 | 2.89 |
KORU Medical Systems currently has a consensus target price of $7.00, indicating a potential upside of 125.81%. Abbott Laboratories has a consensus target price of $118.32, indicating a potential upside of 8.13%. Given KORU Medical Systems’ higher probable upside, research analysts plainly believe KORU Medical Systems is more favorable than Abbott Laboratories.
Summary
Abbott Laboratories beats KORU Medical Systems on 12 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
